US Stocks Movement: Tango Therapeutics plunges on November 12th as Q3 losses widen, collaboration revenue drops to zero, and previous stock gains were significant

Tango Therapeutics November 12 Drop Analysis

Keywords: Q3 loss expands, collaboration revenue drops to zero, large prior gains

1. On November 9, the company released its Q3 2026 financial report, showing a quarterly net loss of $68.4 million, compared to a net profit of $15.9 million in the same period last year. The loss per share was $0.39, marking a significant year-on-year expansion in losses.

2. Collaboration revenue in the third quarter dropped to zero, compared to $53.8 million in the same period last year, which included previously recognized deferred collaboration revenue. Research and general administrative expenses increased, with both revenue and expenses jointly weighing on performance.

3. As of November 12, the company had risen a cumulative 14.47% over the past five days and 169.64% year-to-date. Given the large prior gains, profit-taking pressure emerged after the earnings report was released.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)